TY - JOUR
T1 - Locoregional therapy containing surgery in metastatic breast cancer
T2 - Systematic review and meta-analysis
AU - Rahmani, Jamal
AU - Elhelali, Ala
AU - Yousefi, Morteza
AU - Chavarri-Guerra, Yanin
AU - Ghanavati, Matin
AU - Shadnoush, Mahdi
AU - Akbari, Mohammad Esmaeil
AU - Ardehali, Seyed Hossein
AU - Akbari, Atieh
AU - Barragan-Carrillo, Regina
AU - Hadizadeh, Mohammad
N1 - Publisher Copyright:
© 2023 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland
PY - 2024/2
Y1 - 2024/2
N2 - Introduction: The role of locoregional therapy (LRT) containing surgery and systematic therapy in metastatic breast cancer patients remains controversial. This study investigated the effect of LRT in patients who were initially diagnosed with metastatic breast cancer (MBC) on overall survival (OS), locoregional progression-free survival (PFS), and distant systemic PFS. Methods: The related keywords were searched in MEDLINE/PubMed, SCOPUS, and Web of Science databases up to August 15th, 2022. Hazard ratios (HR) with 95% confidence intervals (CIs) were pooled by the random-effects model. Results: Seven articles with 1626 participants compared LRT with only systemic therapy (ST) for patients with de novo MBC. LRT did not improve (p = 0.28) OS compared to ST (HR: 0.83, 95% CI: 0.60, 1.16). LRT significantly improved locoregional PFS outcomes compared to ST (HR: 0.31, 95% CI: 0.15, 0.60, p = 0.001). LRT significantly (p = 0.001) improved OS in patients with solitary bone metastases (HR: 0.48; 95% CI: 0.35–0.67). Conclusion: LRT improves locoregional PFS. Furthermore, LRT improves OS in patients with solitary bone metastases.
AB - Introduction: The role of locoregional therapy (LRT) containing surgery and systematic therapy in metastatic breast cancer patients remains controversial. This study investigated the effect of LRT in patients who were initially diagnosed with metastatic breast cancer (MBC) on overall survival (OS), locoregional progression-free survival (PFS), and distant systemic PFS. Methods: The related keywords were searched in MEDLINE/PubMed, SCOPUS, and Web of Science databases up to August 15th, 2022. Hazard ratios (HR) with 95% confidence intervals (CIs) were pooled by the random-effects model. Results: Seven articles with 1626 participants compared LRT with only systemic therapy (ST) for patients with de novo MBC. LRT did not improve (p = 0.28) OS compared to ST (HR: 0.83, 95% CI: 0.60, 1.16). LRT significantly improved locoregional PFS outcomes compared to ST (HR: 0.31, 95% CI: 0.15, 0.60, p = 0.001). LRT significantly (p = 0.001) improved OS in patients with solitary bone metastases (HR: 0.48; 95% CI: 0.35–0.67). Conclusion: LRT improves locoregional PFS. Furthermore, LRT improves OS in patients with solitary bone metastases.
KW - Breast cancer
KW - Locoregional therapy
KW - Metastasis
KW - Surgery
KW - Systemic therapy
UR - http://www.scopus.com/inward/record.url?scp=85174523413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174523413&partnerID=8YFLogxK
U2 - 10.1016/j.surge.2023.09.003
DO - 10.1016/j.surge.2023.09.003
M3 - Review article
C2 - 37858431
AN - SCOPUS:85174523413
SN - 1479-666X
VL - 22
SP - 43
EP - 51
JO - Surgeon
JF - Surgeon
IS - 1
ER -